Heron Therapeutics, Inc. Chief Executive Officer and Director Craig A. Collard filed a Form 4 on November 3, 2026, reporting two rounds of restricted stock unit vesting and related tax-withholding disposals on October 30 and October 31, 2026.

Key Highlights

  • RSU vesting on October 30, 2026: 50,021 restricted stock units converted to common stock, followed by 12,181 shares disposed of at $0.28 per share for tax withholding.
  • RSU vesting on October 31, 2026: 34,788 restricted stock units converted to common stock, followed by 8,471 shares disposed of at $0.28 per share for tax withholding.
  • Resulting ownership: Following all four transactions, Collard directly held 931,086 shares of common stock, according to the filing.
  • Remaining derivative securities: After the two vesting events, Collard held 650,274 RSUs from the January 30, 2026 grant and 313,098 RSUs from a separate grant with a date of grant of January 31, 2025.
  • Grant details: The January 30, 2026 RSU grant totaled 800,337 units, vesting in 16 equal quarterly installments beginning one quarter after the grant date.
  • Filing signed: Kathryn Lester signed the form as attorney-in-fact for Craig Collard on November 3, 2026.

Collard's RSU Vesting and Tax-Withholding Transactions at Heron Therapeutics

According to the Form 4 filed with the SEC, Craig A. Collard, who serves as both Chief Executive Officer and Director of Heron Therapeutics, Inc. (NASDAQ:HRTX), reported a series of transactions on October 30 and October 31, 2026. On October 30, 2026, 50,021 restricted stock units vested and converted to common stock under transaction code M. Immediately following, 12,181 shares were disposed of under transaction code F at a price of $0.28 per share, a disposal type commonly associated with share withholding to satisfy tax obligations. After these two transactions, the filing showed Collard directly owned 904,769 shares.

On October 31, 2026, a second vesting event occurred: 34,788 RSUs converted to common stock, again under transaction code M. A further 8,471 shares were then disposed of at $0.28 per share under transaction code F. Following these transactions, Collard's direct beneficial ownership stood at 931,086 shares of common stock, as reported in the filing.

The filing explains that the October 30 vesting relates to an 800,337-RSU grant made on January 30, 2026, vesting in 16 equal quarterly installments beginning one quarter after the grant date. The October 31 vesting relates to a separate RSU grant with a date of grant of January 31, 2025, also vesting in 16 equal quarterly installments beginning one quarter after grant. Each restricted stock unit represents, according to the filing, "a contingent right to receive one share of common stock."

What Was Disclosed

The filing disclosed two RSU vesting events and two corresponding share disposals by Heron Therapeutics CEO Craig A. Collard on October 30 and October 31, 2026, resulting in direct beneficial ownership of 931,086 common shares and remaining RSU balances of 650,274 and 313,098 units from two separate grants.